Literature DB >> 6171337

Cellular immune defects to Epstein-Barr virus-determined antigens in young males.

M G Masucci, R Szigeti, I Ernberg, G Masucci, G Klein, J Chessels, C Sieff, S Lie, A Glomstein, L Businco, W Henle, G Henle, G Pearson, K Sakamoto, D T Purtilo.   

Abstract

Three males with the X-linked lymphoproliferative syndrome (XLP) with hypo- or agammaglobulinemia following Epstein-Barr virus (EBV) infection and two males with the chronic mononucleosis syndrome were investigated for immune responses to EBV-determined antigens. Males with XLP showed profound cellular immune defects. Markedly diminished responses of natural killer cell and interferon-activated killer cell activities and impaired leukocyte migration inhibition responses to phytohemagglutinin were determined in patients with XLP. The two patients with chronic mononucleosis showed less severe defects. All patients showed partial or complete impairment of their EBV-specific immune responses as measured by leukocyte migration inhibition. EBV-specific antibodies were markedly diminished against EBV-associated nuclear antigen, early antigen, and viral capsid antigen in males with XLP. In contrast, patients with chronic mononucleosis had elevated antibodies to most EBV-specific antigens. Individuals with life-threatening EBV-induced lymphoproliferative disorders may exhibit multiple defective immune mechanisms against the virus.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6171337

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Cell-mediated immunity against Epstein-Barr virus infected B lymphocytes.

Authors:  E Klein; M G Masucci
Journal:  Springer Semin Immunopathol       Date:  1982

Review 2.  Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine.

Authors:  M A Epstein; A J Morgan
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

3.  Immunopathology of virally induced tumors. I. Introduction.

Authors:  G Klein
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Studies of EBV-lymphoid cell interactions in two patients with the X-linked lymphoproliferative syndrome: normal EBV-specific HLA-restricted cytotoxicity.

Authors:  F Rousset; G Souillet; M G Roncarolo; J P Lamelin
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

5.  Demonstration of Epstein-Barr virus in primary brain lymphoma by in situ DNA hybridisation in paraffin wax embedded tissue.

Authors:  J K Murphy; L S Young; I S Bevan; F A Lewis; D Dockey; J W Ironside; C J O'Brien; M Wells
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

6.  The proapoptotic function of SAP provides a clue to the clinical picture of X-linked lymphoproliferative disease.

Authors:  Noémi Nagy; Liudmila Matskova; Loránd L Kis; Ulf Hellman; George Klein; Eva Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-01       Impact factor: 11.205

Review 7.  Epstein-Barr virus (EBV)-specific cell-mediated and humoral immune responses in ataxia-telangectasia patients.

Authors:  G Masucci; I Berkel; M G Masucci; I Ernberg; R Szigeti; F Ersoy; O Sanal; O Yegin; G Henle; W Henle
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

8.  Use of enzyme-linked immunosorbent assays with chimeric fusion proteins to titrate antibodies against Epstein-Barr virus nuclear antigen 1.

Authors:  N Inoue; J Kuranari; S Harada; H Nakajima; M Ohbayashi; Y Nakamura; N Miyasaka; K Ezawa; F Ban; K Yanagi
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.